Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Director Jill M. Quigley Sells 17,235 Shares

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Director Jill M. Quigley sold 17,235 shares of the firm’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $10.00, for a total transaction of $172,350.00. Following the completion of the transaction, the director now directly owns 15,000 shares of the company’s stock, valued at $150,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Terns Pharmaceuticals Price Performance

TERN stock opened at $10.68 on Thursday. Terns Pharmaceuticals, Inc. has a 1-year low of $3.26 and a 1-year high of $11.40. The business has a 50-day moving average price of $7.97 and a 200 day moving average price of $6.92. The company has a market capitalization of $690.78 million, a P/E ratio of -8.48 and a beta of -0.37.

Terns Pharmaceuticals (NASDAQ:TERN) last released its quarterly earnings data on Monday, August 5th. The company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.04. On average, analysts anticipate that Terns Pharmaceuticals, Inc. will post -1.31 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on TERN shares. BMO Capital Markets restated an “outperform” rating and issued a $19.00 price target on shares of Terns Pharmaceuticals in a research report on Tuesday, August 6th. JMP Securities increased their target price on shares of Terns Pharmaceuticals from $15.00 to $20.00 and gave the company a “market outperform” rating in a research note on Tuesday. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $14.50.

Institutional Investors Weigh In On Terns Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in TERN. Price T Rowe Associates Inc. MD increased its position in Terns Pharmaceuticals by 12.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 20,694 shares of the company’s stock valued at $136,000 after buying an additional 2,261 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Terns Pharmaceuticals by 66.3% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 11,889 shares of the company’s stock valued at $78,000 after purchasing an additional 4,742 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in Terns Pharmaceuticals by 28.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,645 shares of the company’s stock worth $154,000 after purchasing an additional 5,049 shares in the last quarter. American Century Companies Inc. grew its position in Terns Pharmaceuticals by 17.7% during the 2nd quarter. American Century Companies Inc. now owns 64,119 shares of the company’s stock worth $437,000 after purchasing an additional 9,635 shares during the last quarter. Finally, Simplicity Wealth LLC acquired a new position in Terns Pharmaceuticals during the 2nd quarter valued at approximately $72,000. Institutional investors own 98.26% of the company’s stock.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.